This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
USANA Health Sciences (USNA) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -16.92% and 2.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
USNA vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA vs. STVN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
USNA vs. STVN: Which Stock Is the Better Value Option?
USNA or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. STVN: Which Stock Is the Better Value Option?
USANA Health Sciences (USNA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 24.64% and 2.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Indivior (INDV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 67.31% and 6.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -7.81% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: USANA Health Sciences (USNA) Q3 Earnings Expected to Decline
by Zacks Equity Research
USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
USNA or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. STVN: Which Stock Is the Better Value Option?
USNA vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USANA Health Sciences (USNA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 27.14% and 5.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About USANA Health (USNA) Rating Upgrade to Buy
by Zacks Equity Research
USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
USANA Health Sciences (USNA) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of -4.76% and 0.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate USANA Health Sciences (USNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
USANA Health Sciences (USNA) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 0.88% and 0.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for USANA Health Sciences (USNA) This Earnings Season?
by Zacks Equity Research
USANA Health Sciences (USNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
USANA Health Sciences (USNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
USANA Health (USNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -35.71% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?